Behavioral effects of the novel cannabinoid full agonist AM 411

Pharmacology Biochemistry and Behavior

Volumn 81, Issue 1, 2005, Pages 78-88

  McLaughlin, Peter J ^a   Lu, Dai ^a,b   Winston, Keisha M ^a,b   Thakur, Ganesh ^a,b   Swezey, Lynn A ^a   Makriyannis, Alexandros ^a,b   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Analgesia; Anandamide; Anxiety; Hypothermia; Motor; Tetrahydrocannabinol

Indexed keywords

1 ADAMANTYL DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; METHANANDAMIDE; UNCLASSIFIED DRUG;

AGONIST; ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DRUG SENSITIVITY; HYPOTHERMIA; HYPOTHESIS; INHIBITION KINETICS; INSTRUMENTAL CONDITIONING; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; TASK PERFORMANCE; TRANQUILIZING ACTIVITY;

ADAMANTANE; ANIMALS; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MOTOR ACTIVITY; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

EID: 19344362224     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.02.005     Document Type: Article

References (68)

1. C. Arévalo, R. de Miguel, and R. Hernández-Tristán Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters Pharmacol Biochem Behav 70 2001 123 131
2. M.N. Arizzi, K.M. Cervone, J.E. Aberman, A. Betz, Q. Liu, and S. Lin Behavioral effects of inhibition of cannabinoid metabolism: the amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide Life Sci 74 2004 1001 1011
3. D. Baker, G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, and A. Makriyannis Endocannabinoids control spasticity in a multiple sclerosis model FASEB J 15 2001 300 302
4. 9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice J Pharmacol Exp Ther 309 2004 86 91
5. J.E. Beal, R. Olson, L. Laubenstein, J.O. Morales, P. Bellman, and B. Yangco Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS J Pain Symptom Manage 10 1995 89 97
6. C.S. Breivogel, G. Griffin, V. Di Marzo, and B.R. Martin Evidence for a new G protein-coupled cannabinoid receptor in mouse brain Mol Pharmacol 60 2001 155 163
7. D.L. Carriero, G. Outslay, A.J. Mayorga, J. Aberman, G. Gianutsos, and J.D. Salamone Motor dysfunction produced by tacrine administration in rats Pharmacol Biochem Behav 58 1997 851 858
8. D. Carriero, J. Aberman, S.Y. Lin, A. Hill, A. Makriyannis, and J.D. Salamone A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing Psychopharmacology 137 1998 147 156
9. S.R. Childers, and C.S. Breivogel Cannabis and endogenous cannabinoid systems Drug Alcohol Depend 51 1998 173 187
10. P. Consroe, R. Musty, J. Rein, W. Tillery, and R. Pertwee The perceived effects of smoked cannabis on patients with multiple sclerosis Eur Neurol 38 1997 44 48
11. M. Correa, S. Mingote, A. Betz, A. Wisniecki, and J.D. Salamone Substantia nigra pars reticulata GABA is involved in the regulation of operant lever pressing: pharmacological and microdialysis studies Neuroscience 119 2003 759 766
12. M. Correa, M.N. Arizzi, A. Betz, S. Mingote, and J.D. Salamone Open field locomotor effects in rats after intraventricular injections of ethanol and the ethanol metabolites acetaldehyde and acetate Brain Res Bull 62 2003 197 202
13. M.S. Cousins, and J.D. Salamone Skilled motor deficits in rats induced by ventrolateral striatal dopamine depletions: behavioral and pharmacological characterization Brain Res 732 1996 186 194
14. 1 receptor in the mouse Brain Res 864 2000 186 194
15. A. Degroot, and G.G. Nomikos Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test Eur J Neurosci 20 2004 1059 1064
16. W.A. Devane, A. Breuer, T. Sheskin, T.U. Järbe, M.S. Eisen, and R. Mechoulam A novel probe for the cannabinoid receptor J Med Chem 35 1992 2065 2069
17. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, and G. Griffin Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
18. 1 vanilloid receptor "hybrid" ligands Biochem Biophys Res Commun 281 2001 444 451
19. 1 antagonist SR141716A in a rat Parkinson's model Neurobiol Dis 16 2004 377 385
20. C.S. Freedland, J.S. Poston, and L.J. Porrino Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding Pharmacol Biochem Behav 67 2000 265 270
21. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors Eur J Pharmacol 307 1996 331 338
22. R.F. Genn, S. Tucci, S. Parikh, and S.E. File Effects of nicotine and a cannabinoid receptor agonist on negative contrast: distinction between anxiety and disappointment? Psychopharmacology 177 2004 93 99
23. N. Hajos, and T.F. Freund Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers Neuropharmacology 43 2002 503 510
24. J. Haller, N. Bakos, M. Szirmay, C. Ledent, and T.F. Freund The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety Eur J Neurosci 16 2002 1395 1398
25. R.E. Hampson, J.D. Simeral, E.J. Kelly, and S.A. Deadwyler Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons Hippocampus 13 2003 543 556
26. L. Hanus, A. Breuer, S. Tchilibon, S. Shiloah, D. Goldenberg, and M. Horowitz HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor Proc Natl Acad Sci U S A 96 1999 14228 14233
27. C.J. Heyser, R.E. Hampson, and S.A. Deadwyler Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells J Pharmacol Exp Ther 264 1993 294 307
28. A.L. Hildebrandt, D.M. Kelly-Sullivan, and S.C. Black Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice Eur J Pharmacol 462 2003 125 132
29. C.J. Hillard, S. Manna, M.J. Greenberg, R. DiCamelli, R.A. Ross, and L.A. Stevenson Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1) J Pharmacol Exp Ther 289 1999 1427 1433
30. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, and W.A. Devane International union of pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol Rev 54 2002 161 202
31. M.M. Ibrahim, H. Deng, A. Zvonok, D.A. Cockayne, J. Kwan, and H.P. Mata Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS Proc Natl Acad Sci U S A 100 2003 10529 10533
32. 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited Pharmacol Biochem Behav 73 2002 911 919
33. T.U. Järbe, N.V. DiPatrizio, and A. Makriyannis (-)-Adamantyl- Delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats Behav Pharmacol 15 2004 517 521
34. L.M. Johanek, and D.A. Simone Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury Pain 109 2004 432 442
35. M.R. Johnson, and L.S. Melvin The discovery of nonclassical cannabinoid analgetics R. Mechoulam Cannabinoids as therapeutic agents 1986 CRC Press Inc. Boca Raton, FL
36. M.D. Julian, A.B. Martin, B. Cuellar, F. Rodriguez de Fonseca, M. Navarro, and R. Moratalla Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia Neuroscience 119 2003 309 318
37. I. Katona, B. Sperlagh, A. Sik, A. Kafalvi, E.S. Vizi, and K. Mackie Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons J Neurosci 19 1999 4544 4558
38. G. Keppel Design and analysis: a researcher's handbook 1982 Prentice-Hall Englewood Cliffs, NJ
39. A.D. Khanolkar, V. Abadji, S. Lin, W.A. Hill, G. Taha, and K. Abouzid Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand J Med Chem 39 1996 4515 4519
40. A.D. Khanolkar, S.L. Palmer, and A. Makriyannis Molecular probes for the cannabinoid receptors Chem Phys Lipids 108 2000 37 52
41. J. Killestein, E.L. Hoogervorst, M. Reif, N.F. Kalkers, A.C. Van Loenen, and P.G. Staats Safety, tolerability, and efficacy of orally administered cannabinoids in MS Neurology 58 2002 1404 1407
42. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.F. Aubert, and F. Beslot Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401 404
43. R.M. Liao, and S.C. Fowler Haloperidol produces within-session increments in operant response duration in rats Pharmacol Biochem Behav 36 1990 191 201
44. T. Luk, W. Jin, A. Zvonok, D. Lu, X.Z. Lin, and C. Chavkin Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist Br J Pharmacol 142 2004 495 500
45. T.P. Malan, M.M. Ibrahim, H. Deng, Q. Liu, H.P. Mata, and T. Vanderah CB2 cannabinoid receptor-mediated peripheral antinociception Pain 93 2001 239 245
46. T.P. Malan, M.M. Ibrahim, T.W. Vanderah, A. Makriyannis, and F. Porreca Inhibition of pain responses by activation of CB(2) cannabinoid receptors Chem Phys Lipids 121 2002 191 200
47. G. Marsicano, and B. Lutz Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain Eur J Neurosci 11 1999 4213 4225
48. B.R. Martin, D.R. Compton, B.F. Thomas, W.R. Prescott, P.J. Little, and R.K. Razdan Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs Pharmacol Biochem Behav 40 1991 471 478
49. M. Martin, C. Ledent, M. Parmentier, R. Maldonado, and O. Valverde Involvement of CB1 cannabinoid receptors in emotional behaviour Psychopharmacology 159 2002 379 387
50. P.J. McLaughlin, K. Winston, L. Swezey, A. Wisniecki, J. Aberman, and D.J. Tardif The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats Behav Pharmacol 14 2003 583 588
51. McLaughlin PJ, Winston KM, Limebeer CL, Makriyannis A, Salamone JD. The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology [in press].
52. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, and A.R. Schatz Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem Pharmacol 50 1995 83 90
53. K.R. Muller-Vahl, U. Schneider, A. Koblenz, M. Jobges, H. Kolbe, and T. Daldrup Treatment of Tourette's syndrome with delta 9-tetrahydrocannabinol (THC): a randomized crossover trial Pharmacopsychiatry 35 2002 57 61
54. K. Nelson, D. Walsh, P. Deeter, and F. Sheehan A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia J Palliat Care 10 1994 14 18
55. G. Presburger, and J.K. Robinson Spatial signal detection in rats is differentially disrupted by Δ-9-tetrahydrocannabinol, scopolamine, and MK-801 Behav Brain Res 99 1999 27 34
56. L. Prut, and C. Belzung The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review Eur J Pharmacol 463 2003 3 33
57. M. Rinaldi-Carmona, F. Barth, M. Heaulme, D. Shire, B. Calandra, and C. Congy SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett 350 1994 240 244
58. J. Romero, L. Garcia, M. Cebeira, D. Zadrozny, J.J. Fernandez-Ruiz, and J.A. Ramos The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons Life Sci 56 1995 2033 2040
59. J. Romero, E. Garcia-Palomero, S.Y. Lin, J.A. Ramos, A. Makriyannis, and J.J. Fernandez-Ruiz Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand Life Sci 58 1996 1249 1257
60. J.D. Salamone, P.A. Kurth, L.D. McCullough, J.D. Sokolowski, and M.S. Cousins The role of brain dopamine in response initiation: effects of haloperidol and regionally specific dopamine depletions on the local rate of instrumental responding Brain Res 628 1993 218 226
61. M.C. Sanudo-Peña, K. Tsou, and J.M. Walker Motor actions of cannabinoids in the basal ganglia output nuclei Life Sci 65 1999 703 713
62. C. Tartal, J. Steed, D. Hurst, D. Lu, A. Makriyannis, and P. Reggio Molecular basis for cannabinoid receptor sub-type selectivity of AM411 and AM756 Presented at the 12th annual ICRS symposium on the cannabinoids Pacific Grove, CA, 2002 2002
63. L. Volicer, M. Stelly, J. Morris, J. McLaughlin, and B.J. Volicer Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease Int J Geriatr Psychiatry 12 1997 913 919
64. S.J. Ward, S.R. Childers, and M. Pacheco Pravadoline and aminoalkylindole (AAI) analogues: actions which suggest a receptor interaction Br J Pharmacol 98 1989 831P Suppl.
65. J.L. Wiley, and B.R. Martin Cannabinoid pharmacological properties common to other centrally acting drugs Eur J Pharmacol 471 2003 185 193
66. 9-THC and anandamide Physiol Behav 76 2002 241 250
67. M.H. Yoon, and J.I. Choi Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test Anesthesiology 99 2003 701 707
68. A. Zimmer, A.M. Zimmer, A.G. Hohmann, M. Herkenham, and T.I. Bonner Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice Proc Natl Acad Sci U S A 96 1999 5780 5785